EV race heats up; Ferrari enters the EURO STOXX 50

In addition to intense competition in China’s EV, the general competition is heating up reminded at the weekend Munich Motor Show. Here, Mercedes presented their almost in production concept CLA sedan which is rated to go more than 750 kilometers on a charge beating Tesla’s newest upgrade to its Model 3. BMW also introduced new EV models at the Munich Motor Show. Both Mercedes and BMW are bolstering their line-up in the luxury segment which for now has escaped the intense price war that has started in the volume segment where Tesla’s Model 3 is competing. For Tesla shareholders the key thing to watch over the coming quarters is the market share developments. Tesla had roughly 32% market share in battery electric vehicles in 2022 which it has maintained so far in 2023, but should this slip over the coming year then it could change the narrative around the stock.

Ferrari added to EURO STOXX 50 and Novo Nordisk becomes most valuable European company

Staying with the car theme, Qontigo (part of Deutsche Börse and owner of the EURO STOXX 50 Index) announced on Friday that Ferrari and Saint Gobain will be added to the EURO STOXX 50 Index effective 18 September 2023  while Vonovia and CRH will be deleted from the index. With Ferrari entering the most prestigious equity market benchmark marks the pinnacle of a fantastic growth journey since its IPO in 2016 with 12-month trailing revenue at €5.5bn up from €3.1bn in FY16 and 12-month trailing EBITDA at €2bn up from €874mn in FY16 highlighting the strong growth in the ultra-high-end of the luxury car market.

On Friday, Novo Nordisk became the most valuable European company stealing the limelight from ASML and LVMH that were the previous holders. Novo Nordisk’s market value is around €394bn in today’s session compared to LVMH at €390bn. The rise of Novo Nordisk over the previous two years riding the galloping demand for its obesity drug Wegovy has put health care companies, more specifically pharmaceuticals, to the top of European equity markets. Among the 10 most valuable companies in the STOXX 600 Index, four of those are now pharmaceutical companies (Novo Nordisk, Roche, Novartis, and AstraZeneca. As we have highlighted many times before the European equity market is more well-diversified than the US equity market and also have a higher exposure to defensive sectors that will do well in a downturn. It is not inconceivable that Novo Nordisk’s market value over time could eclipse that of many US technology companies as the company is fundamentally solving a far bigger problem that many technology companies. Novo Nordisk’s market value of $432bn is not far from Meta at $763bn (which was as low as $314bn at the end of 2022).